RT Journal Article SR Electronic T1 Short-term drop in antibody titer after the third dose of SARS-CoV-2 BNT162b2 vaccine in adults JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.03.07.22272028 DO 10.1101/2022.03.07.22272028 A1 Herzberg, Jonas A1 Fischer, Bastian A1 Becher, Heiko A1 Becker, Ann-Kristin A1 Honarpisheh, Human A1 Guraya, Salman Yousuf A1 Strate, Tim A1 Knabbe, Cornelius YR 2022 UL http://medrxiv.org/content/early/2022/03/10/2022.03.07.22272028.abstract AB Little is known about the longevity of antibodies after a third dose of BNT162b2 (BioNTech/Pfizer). Therefore, the serum antibody levels were evaluated after the third dose of BNT162b2 which dropped significantly within 11 weeks from 4155.59 ± 2373.65 BAU/ml to 2389.10 ± 1433.90 BAU/ml, p-value <0.001 but remained higher than after the second dose.These data underline the positive effect of third dose of BNT162b2 but shows a rapid and significant drop of antibodies within a short span of time.Trial Registration This trial was prospectively registered in the German Clinical Trial Register (DRKS00021270).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the medical association Schleswig-Holstein gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.